Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This locus represents a naturally occurring *readthrough transcription event* between the adjacent genes TIMM23B (translocase of inner mitochondrial membrane 23 homolog B) and AGAP6 (ArfGAP with GTPase domain, ankyrin repeat and PH domain 6). The resulting transcripts contain sequence portions from both parent genes but are predicted to be candidates for *nonsense-mediated decay* (NMD) and are categorized as non-coding RNA (ncRNA)[2]. There is no evidence that this readthrough transcript encodes a functional protein, nor is there evidence to support a role as a druggable or disease-associated biological target[2].\n\nKey contextual note:\n- "TIMM23B-AGAP6 readthrough" is not a conventional drug target. It is an ncRNA, specifically a readthrough product, and is not considered a receptor, enzyme, or other protein-based entity typically targeted for therapy.\n- This entity is primarily noted for its classification as a non-coding RNA with a predicted fate of rapid degradation, and not for any molecular or disease-related function.\n- Listing as a target would be incorrect, reflecting lack of substantial or actionable biological data[2].\n\nIf you need information on the protein-coding genes TIMM23B or AGAP6 individually, those *are* protein-coding genes—TIMM23B, for instance, encodes a component of the inner mitochondrial membrane protein import machinery[1][5]. This readthrough transcript, however, does not.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TIMM23B-AGAP6 readthrough (TIMM23B-AGAP6).